Samuel J Klempner

Samuel J Klempner

UNVERIFIED PROFILE

Are you Samuel J Klempner?   Register this Author

Register author
Samuel J Klempner

Samuel J Klempner

Publications by authors named "Samuel J Klempner"

Are you Samuel J Klempner?   Register this Author

75Publications

2551Reads

22Profile Views

Impact of Postoperative Complication and Completion of Multimodality Therapy on Survival in Patients Undergoing Gastrectomy for Advanced Gastric Cancer.

J Am Coll Surg 2020 Feb 6. Epub 2020 Feb 6.

Department of Surgery, Massachusetts General Hospital, and Harvard Medical School, Boston, MA. Electronic address:

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1016/j.jamcollsurg.2019.12.038DOI Listing
February 2020

Durable Response to Carboplatin, Etoposide, Nivolumab, and Ipilimumab in Metastatic High-Grade Neuroendocrine Carcinoma of the Gallbladder.

Pancreas 2020 Feb;49(2):e19-e20

Department of Internal Medicine Harbor-UCLA Medical Center Torrance, CA Samuel Oschin Comprehensive Cancer Institute Cedars-Sinai Medical Center Los Angeles, CA Departments of Radiation Oncology and Biomedical Sciences Samuel Oschin Comprehensive Cancer Institute Cedars-Sinai Medical Center, CA Samuel Oschin Comprehensive Cancer Institute Cedars-Sinai Medical Center and The Angeles Clinic and Research Institute Los Angeles, CA Samuel Oschin Comprehensive Cancer Institute Cedars-Sinai Medical Center Los Angeles, CA

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1097/MPA.0000000000001480DOI Listing
February 2020

High-level FGFR2 amplification is associated with poor prognosis and Lower response to chemotherapy in gastric cancers.

Pathol Res Pract 2020 Feb 13:152878. Epub 2020 Feb 13.

Division of Hematology-Oncology, Department of Medicine, Samsung Medical Center, Sungkyunkwan University School of Medicine, Seoul, South Korea. Electronic address:

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1016/j.prp.2020.152878DOI Listing
February 2020

Can the Help Match the Hype? KRAS-Specific Inhibitors and Beyond.

Cancer Discov 2020 Jan;10(1):20-22

Divsion of Hematology-Oncology, Massachusetts General Hospital Cancer Center, Boston, Massachusetts.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1158/2159-8290.CD-19-1255DOI Listing
January 2020

Efficacy of PD-1 Blockade in Refractory Microsatellite-Stable Colorectal Cancer With High Tumor Mutation Burden.

Clin Colorectal Cancer 2019 12 4;18(4):307-309. Epub 2019 Sep 4.

Division of Hematology and Oncology, Department of Internal Medicine, UC Davis Comprehensive Cancer Center, Sacramento, CA. Electronic address:

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1016/j.clcc.2019.08.001DOI Listing
December 2019

Sequence, Treat, Repeat: Addressing Resistance in EGFR-Mutant NSCLC.

J Thorac Oncol 2019 Nov;14(11):1875-1877

Massachusetts General Hospital Cancer Center, Boston, Massachusetts; Harvard Medical School, Boston, Massachusetts.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1016/j.jtho.2019.07.014DOI Listing
November 2019

Receptor Tyrosine Kinase Fusions as an Actionable Resistance Mechanism to EGFR TKIs in EGFR-Mutant Non-Small-Cell Lung Cancer.

Trends Cancer 2019 Nov 29;5(11):677-692. Epub 2019 Oct 29.

University of California Irvine School of Medicine, Department of Medicine, Division of Hematology/Oncology, Chao Family Comprehensive Cancer Center, Orange, CA 92868, USA. Electronic address:

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1016/j.trecan.2019.09.008DOI Listing
November 2019

Ramucirumab plus pembrolizumab: can we make the maths work?

Lancet Oncol 2019 Aug 10;20(8):1041-1043. Epub 2019 Jul 10.

Department of Medicine, Division of Hematology-Oncology, University of California Los Angeles, Los Angeles, CA, USA.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1016/S1470-2045(19)30399-7DOI Listing
August 2019

Checkpoint inhibition in advanced gastroesophageal cancer: clinical trial data, molecular subtyping, predictive biomarkers, and the potential of combination therapies.

Transl Gastroenterol Hepatol 2019 27;4:63. Epub 2019 Aug 27.

Samuel Oschin Comprehensive Cancer Institute, Cedars-Sinai Medical Center, Los Angeles, CA, USA.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.21037/tgh.2019.08.04DOI Listing
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC6737389PMC
August 2019

Keeping Checkpoint Inhibitors in Check.

JAMA Netw Open 2019 05 3;2(5):e192546. Epub 2019 May 3.

The Angeles Clinic and Research Institute, Los Angeles, California.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1001/jamanetworkopen.2019.2546DOI Listing
May 2019

Progress and challenges in HER2-positive gastroesophageal adenocarcinoma.

J Hematol Oncol 2019 05 17;12(1):50. Epub 2019 May 17.

Department of Medical Oncology and Therapeutics Research, City of Hope Comprehensive Cancer Center, Bldg. 51, 1500 E. Duarte Rd, Duarte, CA, 91010, USA.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1186/s13045-019-0737-2DOI Listing
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC6525398PMC
May 2019

Initial Report of Second-Line FOLFIRI in Combination with Ramucirumab in Advanced Gastroesophageal Adenocarcinomas: A Multi-Institutional Retrospective Analysis.

Oncologist 2019 04 23;24(4):475-482. Epub 2018 Nov 23.

Department of Medicine, Section of Hematology/Oncology, University of Chicago Medical Center and Biological Sciences, Chicago, Illinois, USA

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1634/theoncologist.2018-0602DOI Listing
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC6459251PMC
April 2019

TNS1-ALK Fusion in a Recurrent, Metastatic Uterine Mesenchymal Tumor Originally Diagnosed as Leiomyosarcoma.

Acta Med Acad 2019 Apr;48(1):116-120

The Angeles Clinic and Research Institute, Los Angeles, CA, USA; Samuel Oschin Comprehensive Cancer Institute, Cedars-Sinai Medical Center, Los Angeles, CA, USA.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.5644/ama2006-124.248DOI Listing
April 2019

Variety Is the Spice of Life, but Maybe Not in Gastroesophageal Adenocarcinomas.

Cancer Discov 2019 02;9(2):166-168

Department of Medicine, Section of Hematology & Oncology, The University of Chicago Medical Center & Biological Sciences, Chicago, Illinois.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1158/2159-8290.CD-18-1447DOI Listing
February 2019

Carving out another slice of the pie: Exceptional response to single agent imatinib in an asian female never-smoker with advanced NSCLC with a de-novo PDGFR-α N848 K mutation.

Lung Cancer 2018 10 31;124:86-89. Epub 2018 Jul 31.

Division of Hematology-Oncology, Department of Medicine, University of California Irvine School of Medicine, Orange, CA 92868, USA; Chao Family Comprehensive Cancer Center, University of California Irvine, Orange, CA 92868, USA. Electronic address:

View Article

Download full-text PDF

Source
https://linkinghub.elsevier.com/retrieve/pii/S01695002183050
Publisher Site
http://dx.doi.org/10.1016/j.lungcan.2018.07.043DOI Listing
October 2018

Advances in immuno-oncology biomarkers for gastroesophageal cancer: Programmed death ligand 1, microsatellite instability, and beyond.

World J Gastroenterol 2018 Jul;24(25):2686-2697

Department of Medical Oncology and Developmental Therapeutics, City of Hope Comprehensive Cancer Center, Duarte, CA 91010, United States.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.3748/wjg.v24.i25.2686DOI Listing
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC6034145PMC
July 2018

Refining the management of resectable esophagogastric cancer: FLOT4, CRITICS, OE05, MAGIC-B and the promise of molecular classification.

J Gastrointest Oncol 2018 Jun;9(3):560-572

Department of Medical Oncology and Therapeutics Research, City of Hope Comprehensive Cancer Center, Duarte, CA, USA.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.21037/jgo.2018.03.01DOI Listing
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC6006028PMC
June 2018

Neoadjuvant Chemotherapy Improves Survival in Patients with Clinical T4b Colon Cancer.

J Gastrointest Surg 2018 02 20;22(2):242-249. Epub 2017 Sep 20.

John Wayne Cancer Institute at Providence St John's Health Center, 2200 Santa Monica Blvd, Santa Monica, CA, 90404, USA.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1007/s11605-017-3566-zDOI Listing
February 2018

Pulse Dose Erlotinib and Zuckerguss Improvement in EGFR-Mutant NSCLC.

J Thorac Oncol 2017 12 31;12(12):1857-1858. Epub 2017 Jul 31.

The Angeles Clinic and Research Institute, Los Angeles, California; Samuel Oschin Comprehensive Cancer Institute, Cedars-Sinai Medical Center, Los Angeles, California. Electronic address:

View Article

Download full-text PDF

Source
https://linkinghub.elsevier.com/retrieve/pii/S15560864173065
Publisher Site
http://dx.doi.org/10.1016/j.jtho.2017.07.024DOI Listing
December 2017

-oriented solvent-front EGFR G796S mutation in tissue and ctDNA in a patient progressing on osimertinib: a case report and review of the literature.

Lung Cancer (Auckl) 2017 6;8:241-247. Epub 2017 Dec 6.

Department of Medicine-Hematology/Oncology, Chao Family Comprehensive Cancer Center, University of California Irvine School of Medicine, Orange, CA, USA.

View Article

Download full-text PDF

Source
https://www.dovepress.com/cis-oriented-solvent-front-egfr-g7
Publisher Site
http://dx.doi.org/10.2147/LCTT.S147129DOI Listing
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC5723122PMC
December 2017

The impact of gender, race, socioeconomic status, and treatment on outcomes in esophageal cancer: A population-based analysis.

J Carcinog 2017 18;16. Epub 2017 Sep 18.

Department of Medicine, Division of Hematology/Oncology, University of California, Irvine, CA, USA.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.4103/jcar.JCar_4_17DOI Listing
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC5615860PMC
September 2017

Correlating programmed death ligand 1 (PD-L1) expression, mismatch repair deficiency, and outcomes across tumor types: implications for immunotherapy.

Oncotarget 2017 Sep 24;8(44):77415-77423. Epub 2017 Aug 24.

Division of Hematology-Oncology, Department of Medicine, Samsung Medical Center, Sungkyunkwan University School of Medicine, Seoul, Korea.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.18632/oncotarget.20492DOI Listing
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC5652789PMC
September 2017

Radiation dermatitis caused by a bolus effect from an abdominal compression device.

Med Dosim 2016 2;41(3):221-4. Epub 2016 Jun 2.

Department of Radiation Oncology, University of California, Irvine Medical Center, Orange, CA. Electronic address:

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1016/j.meddos.2016.02.003DOI Listing
August 2017

PD-1 and PD-L1 as emerging therapeutic targets in gastric cancer: current evidence.

Gastrointest Cancer 2017 5;7:1-11. Epub 2017 May 5.

Samuel Oschin Comprehensive Cancer Institute, Cedars-Sinai Medical Center.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.2147/GICTT.S113525DOI Listing
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC5533281PMC
May 2017

Intracranial Activity of Cabozantinib in MET Exon 14-Positive NSCLC with Brain Metastases.

J Thorac Oncol 2017 01 28;12(1):152-156. Epub 2016 Sep 28.

Chao Family Comprehensive Cancer Center, Department of Medicine, Division of Hematology-Oncology, University of California Irvine School of Medicine, Orange, California.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1016/j.jtho.2016.09.127DOI Listing
January 2017

Targeting the Phosphatidylinositol-3-kinase Pathway in Gastric Cancer: Can Omics Improve Outcomes?

Int Neurourol J 2016 Nov 22;20(Suppl 2):S131-140. Epub 2016 Nov 22.

The Angeles Clinic and Research Institute, Los Angeles, CA, USA.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.5213/inj.1632740.370DOI Listing
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC5169087PMC
November 2016

Focus on Alectinib and Competitor Compounds for Second-Line Therapy in -Rearranged NSCLC.

Front Med (Lausanne) 2016 30;3:65. Epub 2016 Nov 30.

The Angeles Clinic and Research Institute, Los Angeles, CA, USA; Cedars-Sinai Medical Center, Samuel Oschin Comprehensive Cancer Institute, Los Angeles, CA, USA.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.3389/fmed.2016.00065DOI Listing
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC5127851PMC
November 2016

Focal Hepatic Fluorodeoxyglucose Uptake Mimics Liver Metastasis Following External Beam Radiation for Gastroesophageal Cancers: A Case and Review of the Literature.

J Clin Imaging Sci 2016 9;6:30. Epub 2016 Aug 9.

The Angeles Clinic and Research Institute, Los Angeles, CA, USA; Cedars-Sinai Medical Center, Los Angeles, CA, USA.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.4103/2156-7514.188089DOI Listing
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC4995847PMC
September 2016

Alectinib induced CNS radiation necrosis in an ALK+NSCLC patient with a remote (7 years) history of brain radiation.

Lung Cancer 2016 06 26;96:15-8. Epub 2016 Mar 26.

Division of Hematology-Oncology, Department of Medicine, University of California Irvine School of Medicine, Orange, CA 92868, United States; Chao Family Comprehensive Cancer Center, Orange, CA 92868, United States.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1016/j.lungcan.2016.03.008DOI Listing
June 2016

Moving molecular subtypes to the clinic in gastric cancer.

Transl Cancer Res 2016 Jun;5(Suppl 1):S25-S30

The Angeles Clinic and Research Institute, Los Angeles, CA 90025, USA.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.21037/tcr.2016.05.21DOI Listing
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC5540366PMC
June 2016

Profile of rociletinib and its potential in the treatment of non-small-cell lung cancer.

Lung Cancer (Auckl) 2016 18;7:91-97. Epub 2016 May 18.

Angeles Clinic and Research Institute; Cedars-Sinai Medical Center, Los Angeles, CA, USA.

View Article

Download full-text PDF

Source
https://www.dovepress.com/profile-of-rociletinib-and-its-pot
Publisher Site
http://dx.doi.org/10.2147/LCTT.S94337DOI Listing
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC5310702PMC
May 2016

Bone mineral density loss in thoracic and lumbar vertebrae following radiation for abdominal cancers.

Radiother Oncol 2016 Mar 15;118(3):430-6. Epub 2016 Mar 15.

Department of Radiology, University of California Irvine, Orange, USA. Electronic address:

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1016/j.radonc.2016.03.002DOI Listing
March 2016

A novel acquired ALK F1245C mutation confers resistance to crizotinib in ALK-positive NSCLC but is sensitive to ceritinib.

Lung Cancer 2016 Feb 3;92:19-21. Epub 2015 Dec 3.

Chao Family Comprehensive Cancer Center, University of California Irvine School of Medicine, Orange, CA 92868, USA. Electronic address:

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1016/j.lungcan.2015.11.023DOI Listing
February 2016

ALK F1174V mutation confers sensitivity while ALK I1171 mutation confers resistance to alectinib. The importance of serial biopsy post progression.

Lung Cancer 2016 Jan 12;91:70-2. Epub 2015 Sep 12.

Department of Medicine, Division of Hematology-Oncology, University of California Irvine School of Medicine, Orange, CA 92868, USA; Chao Family Comprehensive Cancer Center, University of California Irvine Medical Center, Orange, CA 92868, USA.

View Article

Download full-text PDF

Source
https://linkinghub.elsevier.com/retrieve/pii/S01695002153005
Publisher Site
http://dx.doi.org/10.1016/j.lungcan.2015.09.006DOI Listing
January 2016

Comprehensive Genomic Profiling of Advanced Esophageal Squamous Cell Carcinomas and Esophageal Adenocarcinomas Reveals Similarities and Differences.

Oncologist 2015 Oct 2;20(10):1132-9. Epub 2015 Sep 2.

Foundation Medicine, Inc., Cambridge, Massachusetts, USA; Division of Hematology-Oncology, University of California Irvine, Orange, California, USA; The Ohio State University-James Cancer Hospital, Columbus, Ohio, USA; National Translational Research Group, New York, New York, USA; Albany Medical College, Albany, New York, USA.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1634/theoncologist.2015-0156DOI Listing
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC4591943PMC
October 2015

Immunotherapy for advanced gastric and esophageal cancer: preclinical rationale and ongoing clinical investigations.

J Gastrointest Oncol 2015 Oct;6(5):561-9

1 Department of Medicine, Orange, CA, USA ; 2 Division of Hematology-Oncology, University of California Irvine, Orange, CA 92868, USA.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.3978/j.issn.2078-6891.2015.037DOI Listing
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC4570917PMC
October 2015

Moving molecularly directed therapies to the first-line in ALK-positive lung cancer: crizotinib is just the beginning.

Transl Lung Cancer Res 2015 Oct;4(5):649-52

1 Department of Medicine, Division of Hematology-Oncology, 2 Department of Medicine, University of California Irvine School of Medicine, Orange, CA 92868, USA.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.3978/j.issn.2218-6751.2015.07.03DOI Listing
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC4630509PMC
October 2015

Emergence of RET rearrangement co-existing with activated EGFR mutation in EGFR-mutated NSCLC patients who had progressed on first- or second-generation EGFR TKI.

Lung Cancer 2015 Sep 29;89(3):357-9. Epub 2015 Jun 29.

Division of Hematology-Oncology, Department of Medicine, Chao Comprehensive Cancer Center, University of California Irvine School of Medicine, Orange, CA 92868, USA. Electronic address:

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1016/j.lungcan.2015.06.021DOI Listing
September 2015

Radiation necrosis presenting as pseudoprogression (PsP) during alectinib treatment of previously radiated brain metastases in ALK-positive NSCLC: Implications for disease assessment and management.

Lung Cancer 2015 Jun 30;88(3):355-9. Epub 2015 Mar 30.

Hoag Neurosciences Institute, Director, Hoag Brain Tumor Program, Hoag Memorial Hospital Presbyterian, Newport Beach, CA 92663, United States.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1016/j.lungcan.2015.03.022DOI Listing
June 2015

Anaplastic lymphoma kinase inhibitors in brain metastases from ALK+ non-small cell lung cancer: hitting the target even in the CNS.

Chin Clin Oncol 2015 Jun;4(2):20

Department of Medicine, Division of Hematology-Oncology, Chao Family Comprehensive Cancer Center, University of California Irvine School of Medicine, Orange, CA 92868, USA.

View Article

Download full-text PDF

Source
http://www.thecco.net/article/view/6520/7543
Publisher Site
http://dx.doi.org/10.3978/j.issn.2304-3865.2015.05.03DOI Listing
June 2015

Prospective comprehensive genomic profiling of advanced gastric carcinoma cases reveals frequent clinically relevant genomic alterations and new routes for targeted therapies.

Oncologist 2015 May 16;20(5):499-507. Epub 2015 Apr 16.

Foundation Medicine Inc., Cambridge, Massachusetts, USA; Chao Family Comprehensive Cancer Center, Division of Hematology-Oncology, Department of Medicine, University of California Irvine School of Medicine, Orange, California, USA; Dana-Farber Cancer Institute, Boston, Massachusetts, USA; University of Chicago, Chicago, Illinois, USA; Comprehensive Cancer Centers of Nevada, Las Vegas, Nevada, USA; Department of Pathology and Laboratory Medicine, Albany Medical College, Albany, New York, USA.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1634/theoncologist.2014-0378DOI Listing
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC4425384PMC
May 2015

Identification of a novel HIP1-ALK fusion variant in Non-Small-Cell Lung Cancer (NSCLC) and discovery of ALK I1171 (I1171N/S) mutations in two ALK-rearranged NSCLC patients with resistance to Alectinib.

J Thorac Oncol 2014 Dec;9(12):1821-5

*Division of Hematology-Oncology, Department of Medicine, Chao Family Comprehensive Cancer Center, University of California Irvine School of Medicine, Orange, California; †Foundation Medicine, Inc., Cambridge, Massachusetts; and ‡Departmente of Pathology and Laboratory Medicine, Albany Medical Center, Albany, New York.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1097/JTO.0000000000000368DOI Listing
December 2014

Spontaneous regression of crizotinib-associated complex renal cysts during continuous crizotinib treatment.

Oncologist 2014 Sep 5;19(9):1008-10. Epub 2014 Aug 5.

Chao Family Comprehensive Cancer Center and Division of Hematology Oncology, Department of Medicine, University of California Irvine School of Medicine, Orange, California, USA.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1634/theoncologist.2014-0216DOI Listing
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC4153456PMC
September 2014

Targeted therapy for gastric cancer: molecular pathways and ongoing investigations.

Biochim Biophys Acta 2014 Aug 22;1846(1):232-7. Epub 2014 May 22.

University of California Irvine, Division of Hematology-Oncology, Orange, CA, USA. Electronic address:

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1016/j.bbcan.2014.05.003DOI Listing
August 2014

Next-generation sequencing reveals a Novel NSCLC ALK F1174V mutation and confirms ALK G1202R mutation confers high-level resistance to alectinib (CH5424802/RO5424802) in ALK-rearranged NSCLC patients who progressed on crizotinib.

J Thorac Oncol 2014 Apr;9(4):549-53

*Chao Family Comprehensive Cancer Center, University of California Irvine Medical Center, Orange, California; †Division of Hematology Oncology, Department of Medicine, University of California Irvine School of Medicine, Orange, California; ‡Division of Surgical Oncology, Department of Surgery, University of California Irvine School of Medicine, Orange, California; §Division of Nuclear Medicine, Department of Radiology, University of California Irvine Medical Center, University of California Irvine School of Medicine, Orange, California; and ‖Foundation Medicine Inc, Cambridge, Massachusetts.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1097/JTO.0000000000000094DOI Listing
April 2014

What a tangled web we weave: emerging resistance mechanisms to inhibition of the phosphoinositide 3-kinase pathway.

Cancer Discov 2013 Dec 21;3(12):1345-54. Epub 2013 Nov 21.

1Division of Hematology-Oncology, University of California Irvine Medical Center, Orange, California; 2Division of Signal Transduction, Beth Israel Deaconess Medical Center; 3Department of Medical Oncology, Dana-Farber Cancer Institute, Boston, Massachusetts; and 4Department of Medicine, Weill Cornell Medical College, New York, New York.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1158/2159-8290.CD-13-0063DOI Listing
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC3864542PMC
December 2013

Clinical investigation of receptor and non-receptor tyrosine kinase inhibitors for the treatment of epithelial ovarian cancer.

Expert Opin Pharmacother 2013 Nov 12;14(16):2171-82. Epub 2013 Aug 12.

Beth Israel Deaconess Medical Center, Division of Hematology-Oncology , Boston, MA 02215 , USA.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1517/14656566.2013.826650DOI Listing
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC4103698PMC
November 2013

Safety of cupping during bevacizumab therapy.

J Altern Complement Med 2013 Aug 4;19(8):729-31. Epub 2013 Feb 4.

Department of Medicine, Beth Israel Deaconess Medical Center, Harvard Medical School, Boston, MA 02215, USA.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1089/acm.2011.0791DOI Listing
August 2013

Complementary and alternative medicines in prostate cancer: from bench to bedside?

Oncologist 2012 22;17(6):830-7. Epub 2012 May 22.

Division of Hematology-Oncology, Beth Israel Deaconess Medical Center, 330 Brookline Avenue, Boston, Massachusetts 02215, USA.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1634/theoncologist.2012-0094DOI Listing
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC3380882PMC
November 2012

Severe pazopanib-induced hepatotoxicity: clinical and histologic course in two patients.

J Clin Oncol 2012 Sep 16;30(27):e264-8. Epub 2012 Jul 16.

Beth Israel Deaconess Medical Center, Harvard Medical School, Boston, MA, USA.

View Article

Download full-text PDF

Source
http://ascopubs.org/doi/10.1200/JCO.2011.41.0332
Publisher Site
http://dx.doi.org/10.1200/JCO.2011.41.0332DOI Listing
September 2012

ALK translocation in non-small cell lung cancer with adenocarcinoma and squamous cell carcinoma markers.

J Thorac Oncol 2011 Aug;6(8):1439-40

Division of Hematology/Oncology, Beth Israel Deaconess Medical Center, Harvard Medical School, Boston, Massachusetts, USA.

View Article

Download full-text PDF

Source
https://linkinghub.elsevier.com/retrieve/pii/S15560864153107
Publisher Site
http://dx.doi.org/10.1097/JTO.0b013e3182217c01DOI Listing
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC5018205PMC
August 2011